Skip to main content

Hannah Brendan's Form 4 filing

IRulya Therapeutics Inc.IRLA · filed Aug 21, 2024

Accession no.
0001415889-24-021869
Filed
Aug 21, 2024
Trade date
Aug 19-21, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 6 non-derivative transactions. Open-market purchases total $24.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hannah BrendanCIK 0001929422Officer (CHIEF BUSINESS OFFICER AND COO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 19, 2024Common StockPPurchaseAcquired+2,155$0.58+$1,249.9259,771Direct
Aug 20, 2024Common StockPPurchaseAcquired+2,500$0.61+$1,525262,271Direct
Aug 20, 2024Common StockPPurchaseAcquired+3,424$0.60+$2,054.4265,695Direct
Aug 21, 2024Common StockPPurchaseAcquired+2,280$0.61+$1,390.8267,975Direct
Aug 21, 2024Common StockPPurchaseAcquired+5,000$0.62+$3,100272,975Direct
Aug 21, 2024Common StockPPurchaseAcquired+23,565$0.63+$14,845.95296,540Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)